Group

N

Total tumor volume (mm^{3})

Viable tumor volume (mm^{3})

Necrotic tumor volume (mm^{3})

Necrotic fraction

% CD 31 positive


1

11

5084.7 ± 1257

3776.0 ± 884.4

1308.7 ± 425.9

0.25 ± 0.03

7.50 ± 2.4

2

8

4442.3 ± 884.6

3282.2 ± 691.1

1160.1 ± 268.6

0.26 ± 0.04

6.90 ± 2.0

3

6

4077.5 ± 579.8

2796.4 ± 392.1

1281.1 ± 225.0

0.31 ± 0.03

4.46 ± 1.1

4

9

3598.9 ± 964.2

2475.0 ± 691.7

1123.9 ± 278.3

0.31 ± 0.02

4.37 ± 0.7

5

9

4330.8 ± 295.4

2818.1 ± 614.4

1512.7 ± 304.6

0.35 ± 0.03

3.27 ± 0.8

6

7

3799.0 ± 480.4

2221.8 ± 753.9

1577.2 ± 663.2

0.41 ± 0.07

2.24 ± 1.1

7

8

3958.8 ± 244.6

2534.7 ± 497.8

1424.1 ± 255.7

0.36 ± 0.02

2.99 ± 0.6

8

9

3678.1 ± 599.3

2450.8 ± 397.6

1227.3 ± 290.9

0.33 ± 0.05

3.96 ± 1.5

 Analysis of variance followed by a StudentNewmanKeuls multiple range test showed the following significant difference (p < 0.05) between the group means:
 Volume of viable tumor – the viable tumor volume of group 1 was significantly greater than the viable tumor volume of groups 3 to 8; the viable tumor volume of group 2 was significantly greater than the viable tumor volume of group 6.
 Necrotic fraction – the necrotic fractions of groups 1 and 2 were significantly less than the necrotic fractions of groups 3 and 8; the necrotic fraction of group 6 was significantly greater than the necrotic fraction of all other groups.
 % CD 31 positive – the CD 31 positive areas (volume fraction) of groups 1 and 2 were significantly greater than the CD 31 positive area of groups 3 to 8; the CD 31 positive areas of groups 3 and 4 were significantly greater than the CD 31 positive area of group 6.
 Total tumor volume – the total tumor volume of group 1 was significantly greater than the total tumor mass of all other groups.
 All values are mean ± SD.